Ameritas Investment Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ameritas Investment Partners’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,236	Closed	-$306K	–	3274
2024 Q1	$306K	Hold	7,236	–	–	0.01%	1018
2023 Q4	$307K	Buy	7,236 +1,088	+18%	+$31.3K	0.01%	1015
2023 Q3	$134K	Buy	6,148 +1,038	+20%	+$26K	0.01%	1449
2023 Q2	$162K	Buy	5,110 +526	+11%	+$16.1K	0.01%	1263
2023 Q1	$112K	Hold	4,584	–	–	﹤0.01%	1464
2022 Q4	$149K	Buy	4,584 +508	+12%	+$14.3K	0.01%	1324
2022 Q3	$115K	Hold	4,076	–	–	0.01%	1401
2022 Q2	$107K	Buy	4,076 +1,003	+33%	+$28.5K	﹤0.01%	1466
2022 Q1	$108K	Hold	3,073	–	–	﹤0.01%	1604
2021 Q4	$100K	Hold	3,073	–	–	﹤0.01%	1686
2021 Q3	$91K	Buy	3,073 +308	+11%	+$8.65K	﹤0.01%	1755
2021 Q2	$71K	Buy	+2,765	New	+$39.6K	﹤0.01%	1954

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ameritas Investment Partners's CERE Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 7,236 shares — an estimated $306K sold.

Ameritas Investment Partners first reported a position in CERE in Q2 2021 and held it in 12 quarters. The position peaked at $307K in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

Ameritas Investment Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Ameritas Investment Partners sold 7,236 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $306K.
Ameritas Investment Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
Ameritas Investment Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $307K in Q4 2023.
231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.